In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

Pharmaceutical giant GSK said on Monday that the US Food and Drug Administration has agreed to review its Biologics License ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

(Alliance News) - GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application for depemokimab in two indications - for asthma with type 2 ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The U.S. Food and Drug Administration (FDA) has issued its recommendations to vaccine makers on which virus strains to select when manufacturing influenza (flu) vaccines for the 2025-2026 U.S. flu ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...